More than 200 generic drugs approved by the U.S. Food and Drug Administration for non-cancer indications have shown promise for treating cancer. Due to their long history of safe patient use, low cost, and widespread availability, repurposing of generic drugs represents a major opportunity to rapidly improve outcomes for cancer patients and reduce healthcare costs worldwide. Evidence on the efficacy of non-cancer generic drugs being tested for cancer exists in scientific publications, but trying to manually identify and extract such evidence is intractable. In this paper, we introduce a system to automate this evidence extraction from PubMed abstracts. Our primary contribution is to define the natural language processing pipeline required to obtain such evidence, comprising the following modules: querying, filtering, cancer type entity extraction, therapeutic association classification, and study type classification. Using the subject matter expertise on our team, we create our own datasets for these specialized domain-specific tasks. We obtain promising performance in each of the modules by utilizing modern language modeling techniques and plan to treat them as baseline approaches for future improvement of individual components.

The aim of this paper is to develop a methodology that is useful for analysing from a microeconomic perspective the incentives to entry, permanence and exit in the market for pharmaceutical generics under fuzzy conditions. In an empirical application of our proposed methodology, the potential towards permanence of labs with different characteristics has been estimated. The case we deal with is set in an open market where global players diversify into different national markets of pharmaceutical generics. Risk issues are significantly important in deterring decision makers from expanding in the generic pharmaceutical business. However, not all players are affected in the same way and/or to the same extent. Small, non-diversified generics labs are in the worse position. We have highlighted that the expected NPV and the number of generics in the portfolio of a pharmaceutical lab are important variables, but that it is also important to consider the degree of diversification. Labs with a higher potential for diversification across markets have an advantage over smaller labs. We have described a fuzzy decision support system based on the Mamdani model in order to determine the incentives for a laboratory to remain in the market both when it is stable and when it is growing.